WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Dividends Score
Market Cap
Dividend Yield
Payout Ratio
Last Dividend
Annual Dividend
Dividend Percentile
Dividend Dropped Count (L10Y)
Ex-dividend Date
Div. Payment Date
PULM
PULMATRIX INC
$7.16MN/A0.00%N/AN/AN/AN/A
OCUL
OCULAR THERAPEUTIX INC
$917.03MN/A0.00%N/AN/AN/AN/A
BYSI
BEYONDSPRING INC
$87.82MN/A0.00%N/AN/AN/AN/A
PHAR
PHARMING GROUP NV
$671.07MN/A0.00%N/AN/AN/AN/A
URGN
UROGEN PHARMA LTD
$487.95MN/A0.00%N/AN/AN/AN/A
RXRX
RECURSION PHARMACEUTICALS INC
$2.07BN/A0.00%N/AN/AN/AN/A
MRVI
MARAVAI LIFESCIENCES HOLDINGS INC
$2.26BN/A0.00%N/AN/AN/AN/A
INVA
INNOVIVA INC
$961.06MN/A0.00%$0.2500N/AN/A0
SWTX
SPRINGWORKS THERAPEUTICS INC
$3.34BN/A0.00%N/AN/AN/AN/A
IMRN
IMMURON LTD
$14.35MN/A0.00%N/AN/AN/AN/A
HOWL
WEREWOLF THERAPEUTICS INC
$263.77MN/A0.00%N/AN/AN/AN/A
HOOK
HOOKIPA PHARMA INC
$92.02MN/A0.00%N/AN/AN/AN/A
AADI
AADI BIOSCIENCE INC
$52.05MN/A0.00%N/AN/AN/AN/A
STOK
STOKE THERAPEUTICS INC
$556.57MN/A0.00%N/AN/AN/AN/A
CVAC
CUREVAC NV
$701.08MN/A0.00%N/AN/AN/AN/A
SILO
SILO PHARMA INC
$5.26MN/A0.00%N/AN/AN/AN/A
TARS
TARSUS PHARMACEUTICALS INC
$1.26BN/A0.00%N/AN/AN/AN/A
CLLS
CELLECTIS SA
$214.54MN/A0.00%N/AN/AN/AN/A
RPTX
REPARE THERAPEUTICS INC
$145.53MN/A0.00%N/AN/AN/AN/A
CRVO
CERVOMED INC
$148.46MN/A0.00%N/AN/AN/AN/A
TCRT
ALAUNOS THERAPEUTICS INC
$20.82MN/A0.00%N/AN/AN/AN/A
CANF
CAN-FITE BIOPHARMA LTD
$8.53MN/A0.00%N/AN/AN/AN/A
IPHA
INNATE PHARMA SA
$204.75MN/A0.00%N/AN/AN/AN/A
BRTX
BIORESTORATIVE THERAPIES INC
$9.24MN/A0.00%N/AN/AN/AN/A
BLRX
BIOLINERX LTD
$49.51MN/A0.00%N/AN/AN/AN/A
PSTX
POSEIDA THERAPEUTICS INC
$276.92MN/A0.00%N/AN/AN/AN/A
CRMD
CORMEDIX INC
$321.09MN/A0.00%N/AN/AN/AN/A
KRON
KRONOS BIO INC
$61.30MN/A0.00%N/AN/AN/AN/A
ANNX
ANNEXON INC
$439.32MN/A0.00%N/AN/AN/AN/A
BDTX
BLACK DIAMOND THERAPEUTICS INC
$359.96MN/A0.00%N/AN/AN/AN/A
ACST
ACASTI PHARMA INC
$27.82MN/A0.00%N/AN/AN/AN/A
KTTA
PASITHEA THERAPEUTICS CORP
$7.21MN/A0.00%N/AN/AN/AN/A
VIR
VIR BIOTECHNOLOGY INC
$1.41BN/A0.00%N/AN/AN/AN/A
SNDX
SYNDAX PHARMACEUTICALS INC
$1.87BN/A0.00%N/AN/AN/AN/A
BCYC
BICYCLE THERAPEUTICS PLC
$1.05BN/A0.00%N/AN/AN/AN/A
IPSC
CENTURY THERAPEUTICS INC
$196.40MN/A0.00%N/AN/AN/AN/A
EXAI
EXSCIENTIA PLC
$587.03MN/A0.00%N/AN/AN/AN/A
XBIT
XBIOTECH INC
$258.53MN/A0.00%N/AN/AN/AN/A
ANAB
ANAPTYSBIO INC
$711.36MN/A0.00%N/AN/AN/AN/A
VCEL
VERICEL CORP
$2.31BN/A0.00%N/AN/AN/AN/A
CLSD
CLEARSIDE BIOMEDICAL INC
$97.88MN/A0.00%N/AN/AN/AN/A
ACAD
ACADIA PHARMACEUTICALS INC
$2.81BN/A0.00%N/AN/AN/AN/A
ZNTL
ZENTALIS PHARMACEUTICALS INC
$830.94MN/A0.00%N/AN/AN/AN/A
ABEO
ABEONA THERAPEUTICS INC
$125.83MN/A0.00%N/AN/AN/AN/A
PASG
PASSAGE BIO INC
$72.83MN/A0.00%N/AN/AN/AN/A
ACET
ADICET BIO INC
$119.12MN/A0.00%N/AN/AN/AN/A
EQ
EQUILLIUM INC
$58.88MN/A0.00%N/AN/AN/AN/A
CGON
CG ONCOLOGY INC
$2.42BN/A0.00%N/AN/AN/AN/A
CNTA
CENTESSA PHARMACEUTICALS PLC
$949.90MN/A0.00%N/AN/AN/AN/A
AVIR
ATEA PHARMACEUTICALS INC
$333.29MN/A0.00%N/AN/AN/AN/A
NRIX
NURIX THERAPEUTICS INC
$628.15MN/A0.00%N/AN/AN/AN/A
PMVP
PMV PHARMACEUTICALS INC
$102.37MN/A0.00%N/AN/AN/AN/A
VRCA
VERRICA PHARMACEUTICALS INC
$307.96MN/A0.00%N/AN/AN/AN/A
VXRT
VAXART INC
$126.75MN/A0.00%N/AN/AN/AN/A
CBUS
CIBUS INC
$411.69MN/A0.00%N/AN/AN/AN/A
LPTX
LEAP THERAPEUTICS INC
$81.66MN/A0.00%N/AN/AN/AN/A
LVTX
LAVA THERAPEUTICS NV
$79.66MN/A0.00%N/AN/AN/AN/A
DYAI
DYADIC INTERNATIONAL INC
$41.43MN/A0.00%N/AN/AN/AN/A
CGEM
CULLINAN THERAPEUTICS INC
$1.22BN/A0.00%N/AN/AN/AN/A
KURA
KURA ONCOLOGY INC
$1.57BN/A0.00%N/AN/AN/AN/A
SABS
SAB BIOTHERAPEUTICS INC
$37.18MN/A0.00%N/AN/AN/AN/A
PCSA
PROCESSA PHARMACEUTICALS INC
$6.20MN/A0.00%N/AN/AN/AN/A
ARTL
ARTELO BIOSCIENCES INC
$4.36MN/A0.00%N/AN/AN/AN/A
OMGA
OMEGA THERAPEUTICS INC
$142.30MN/A0.00%N/AN/AN/AN/A
TARA
PROTARA THERAPEUTICS INC
$59.92MN/A0.00%N/AN/AN/AN/A
DOMH
DOMINARI HOLDINGS INC
$13.65MN/A0.00%N/AN/AN/AN/A
ATHA
ATHIRA PHARMA INC
$75.12MN/A0.00%N/AN/AN/AN/A
NKTX
NKARTA INC
$365.68MN/A0.00%N/AN/AN/AN/A
NBTX
NANOBIOTIX SA
$287.51MN/A0.00%N/AN/AN/AN/A
VRAX
VIRAX BIOLABS GROUP LTD
$1.11MN/A0.00%N/AN/AN/AN/A
PCVX
VAXCYTE INC
$7.15BN/A0.00%N/AN/AN/AN/A
LGND
LIGAND PHARMACEUTICALS INC
$1.31BN/AN/AN/AN/AN/AN/A
ADMA
ADMA BIOLOGICS INC
$1.55BN/A0.00%N/AN/AN/AN/A
XENE
XENON PHARMACEUTICALS INC
$3.30BN/A0.00%N/AN/AN/AN/A
BNTC
BENITEC BIOPHARMA INC
$23.20MN/A0.00%$0.4979N/AN/A0
MORF
MORPHIC HOLDING INC
$1.50BN/A0.00%N/AN/AN/AN/A
LTRN
LANTERN PHARMA INC
$66.06MN/A0.00%N/AN/AN/AN/A
LENZ
LENZ THERAPEUTICS INC
$136.94MN/A0.00%N/AN/AN/AN/A
PRLD
PRELUDE THERAPEUTICS INC
$211.99MN/A0.00%N/AN/AN/AN/A
NXTC
NEXTCURE INC
$42.80MN/A0.00%N/AN/AN/AN/A
STRO
SUTRO BIOPHARMA INC
$239.15MN/A0.00%N/AN/AN/AN/A
ORIC
ORIC PHARMACEUTICALS INC
$654.22MN/A0.00%N/AN/AN/AN/A
GDTC
CYTOMED THERAPEUTICS LTD
$23.71MN/A0.00%N/AN/AN/AN/A
BCRX
BIOCRYST PHARMACEUTICALS INC
$917.37MN/A0.00%N/AN/AN/AN/A
TYRA
TYRA BIOSCIENCES INC
$937.50MN/A0.00%N/AN/AN/AN/A
IPA
IMMUNOPRECISE ANTIBODIES LTD
$33.68MN/A0.00%N/AN/AN/AN/A
CMPX
COMPASS THERAPEUTICS INC
$233.90MN/A0.00%N/AN/AN/AN/A
ERAS
ERASCA INC
$324.20MN/A0.00%N/AN/AN/AN/A
GPCR
STRUCTURE THERAPEUTICS INC
$1.83BN/A0.00%N/AN/AN/AN/A
QNCX
QUINCE THERAPEUTICS INC
$42.57MN/A0.00%N/AN/AN/AN/A
AURA
AURA BIOSCIENCES INC
$390.59MN/A0.00%N/AN/AN/AN/A
ALDX
ALDEYRA THERAPEUTICS INC
$247.16MN/A0.00%N/AN/AN/AN/A
EPIX
ESSA PHARMA INC
$304.36MN/A0.00%N/AN/AN/AN/A
ENTX
ENTERA BIO LTD
$76.64MN/A0.00%N/AN/AN/AN/A
SNPX
SYNAPTOGENIX INC
$5.52MN/A0.00%N/AN/AN/AN/A
WVE
WAVE LIFE SCIENCES LTD
$750.82MN/A0.00%N/AN/AN/AN/A
ABOS
ACUMEN PHARMACEUTICALS INC
$209.68MN/A0.00%N/AN/AN/AN/A
CDTX
CIDARA THERAPEUTICS INC
$57.07MN/A0.00%N/AN/AN/AN/A
LRMR
LARIMAR THERAPEUTICS INC
$495.41MN/A0.00%N/AN/AN/AN/A
VRNA
VERONA PHARMA PLC
$1.27BN/A0.00%N/AN/AN/AN/A

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in May 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Corcept Therapeutics (NASDAQ:CORT)


Corcept Therapeutics (NASDAQ:CORT) is the top biotech stock with a Zen Score of 65, which is 42 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Corcept Therapeutics has seen its stock return 6.15% over the past year, overperforming other biotech stocks by 24 percentage points.

Corcept Therapeutics has an average 1 year price target of $40.67, an upside of 65.85% from Corcept Therapeutics's current stock price of $24.52.

Corcept Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Corcept Therapeutics, 66.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the second best biotech stock with a Zen Score of 64, which is 41 points higher than the biotech industry average of 23. It passed 20 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -20.99% over the past year, underperforming other biotech stocks by -3 percentage points.

Incyte has an average 1 year price target of $74.92, an upside of 39.37% from Incyte's current stock price of $53.76.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Incyte, 30.77% have issued a Strong Buy rating, 23.08% have issued a Buy, 46.15% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Amylyx Pharmaceuticals (NASDAQ:AMLX)


Amylyx Pharmaceuticals (NASDAQ:AMLX) is the third best biotech stock with a Zen Score of 63, which is 40 points higher than the biotech industry average of 23. It passed 20 out of 33 due diligence checks and has strong fundamentals. Amylyx Pharmaceuticals has seen its stock lose -92.77% over the past year, underperforming other biotech stocks by -74 percentage points.

Amylyx Pharmaceuticals has an average 1 year price target of $11.00, an upside of 441.87% from Amylyx Pharmaceuticals's current stock price of $2.03.

Amylyx Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Amylyx Pharmaceuticals, 40% have issued a Strong Buy rating, 20% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 3 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 57.19%, which is 42 percentage points higher than the biotech industry average of 15.03%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

2. Novo Nordisk A S (NYSE:NVO)


Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.11%, which is -14 percentage points lower than the biotech industry average of 15.03%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 47.8% indicates that its dividend yield is sustainable for the long-term.

3. Bio Techne (NASDAQ:TECH)


Bio Techne (NASDAQ:TECH) has an annual dividend yield of 0.41%, which is -15 percentage points lower than the biotech industry average of 15.03%. Bio Techne's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Bio Techne's dividend has shown consistent growth over the last 10 years.

Bio Techne's dividend payout ratio of 22.7% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 1.07% in the last day, and up 6% over the last week. Ardelyx was the among the top gainers in the biotechnology industry, gaining 28.42% yesterday.

Ardelyx shares are trading higher after the company reported better-than-expected Q1 financial results.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 73 points higher than the biotech industry average of 13. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -20.99% in the past year. It has underperformed other stocks in the biotech industry by -3 percentage points.

2. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 86, which is 73 points higher than the biotech industry average of 13. It passed 6 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -19.61% in the past year. It has underperformed other stocks in the biotech industry by -1 percentage points.

3. Amylyx Pharmaceuticals (NASDAQ:AMLX)


Amylyx Pharmaceuticals (NASDAQ:AMLX) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Amylyx Pharmaceuticals has a valuation score of 71, which is 58 points higher than the biotech industry average of 13. It passed 5 out of 7 valuation due diligence checks.

Amylyx Pharmaceuticals's stock has dropped -92.77% in the past year. It has underperformed other stocks in the biotech industry by -74 percentage points.

Are biotech stocks a good buy now?

50.1% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 80.46% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 6.05x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.